Form 4: Esperion CFO Awarded Equity and Stock Options

Esperion Therapeutics' CFO, Benjamin Halladay, was granted 247,430 shares of common stock and options for 221,270 shares, vesting over four years.

Summary

• Benjamin Halladay, Chief Financial Officer of Esperion Therapeutics, Inc. (ESPR), was granted 247,430 shares of common stock.
• The common stock award has a price of $0 and will vest over a four-year period in equal quarterly installments, with the first installment on June 15, 2026.
• Following this transaction, Mr. Halladay beneficially owns 720,026 shares of common stock, which includes 5,071 shares recently acquired through Esperion's Employee Stock Purchase Plan.
• Mr. Halladay was also granted stock options to purchase 221,270 shares of common stock at an exercise price of $2.44 per share.
• These stock options also have a price of $0 and will vest over a four-year period in equal quarterly installments, with the first installment on June 15, 2026.
• The stock options become exercisable on March 13, 2026, and expire on March 13, 2036.
• Following this transaction, Mr. Halladay beneficially owns 221,270 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a standard executive compensation practice that aligns management incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The equity and option grants align the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule over four years encourages retention of key management personnel.

Future Outlook

The common stock award and stock options will vest over a four-year period in equal quarterly installments, with the first vesting event scheduled for June 15, 2026. The stock options have an expiration date of March 13, 2036.

Management Comments

• The undersigned hereby constitutes and appoints each of Sheldon Koenig and Benjamin Looker, signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to execute SEC forms on behalf of Benjamin Halladay.

Industry Context

StockSavvy.ai notes that equity and option grants to executive officers are a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and motivate talent while aligning their interests with long-term shareholder value creation.

Comparison to Industry Standards

• Equity grants and stock options are common compensation tools for CFOs in the biotech sector, similar to practices at companies like Amgen or Gilead Sciences, where executive compensation often includes a significant equity component.
• The four-year vesting schedule is a typical industry standard for executive equity awards, promoting long-term commitment and performance, comparable to vesting schedules seen at companies such as Moderna or Pfizer for similar roles.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the CFO's financial interests with long-term shareholder value, potentially leading to more focused strategic decisions.
• Employees: The inclusion of shares from the Employee Stock Purchase Plan indicates broader employee participation in company ownership, which can boost morale and retention.

Next Steps

• The common stock and stock options will begin vesting in equal quarterly installments starting June 15, 2026, over a four-year period.

Key Dates

Keywords

Esperion Therapeutics, ESPR, Benjamin Halladay, Chief Financial Officer, CFO, Equity Grant, Stock Options, Insider Transaction, Form 4, Executive Compensation, Vesting Schedule, Employee Stock Purchase Plan